Cogent Biosciences Inc.
(COGT)
undefined
undefined%
At close: undefined
8.15
-0.85%
After-hours Dec 13, 2024, 04:15 PM EST
Company Description
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases.
Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors.
It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib.
The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020.
Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Cogent Biosciences Inc.
| Country | United States |
| IPO Date | Mar 29, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 164 |
| CEO | Andrew R. Robbins M.B.A. |
Contact Details
Address: 200 Cambridge Park Drive Cambridge, Massachusetts United States | |
| Website | https://www.cogentbio.com |
Stock Details
| Ticker Symbol | COGT |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001622229 |
| CUSIP Number | 19240Q201 |
| ISIN Number | US19240Q2012 |
| Employer ID | 46-5308248 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Andrew R. Robbins M.B.A. | President, Chief Executive Officer & Director |
| Brad Barnett | Chief Technology Officer |
| Erin Schellhammer | Chief People Officer |
| Evan D. Kearns J.D. | Chief Legal Officer & Corporate Secretary |
| John L. Green C.A., CPA | Chief Financial Officer & Principal Accounting Officer |
| Brad Fell | Senior Vice President of Chemistry |
| Christi Waarich | Senior Director of Investor Relations |
| Dana R. Martin Pharm.D. | Senior Vice President of Medical Affairs & Chief Patient Officer |
| Dr. Jessica Sachs M.D. | Chief Medical Officer |
| Dr. John Edward Robinson Ph.D. | Chief Scientific Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 09, 2024 | 8-K | Current Report |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 12, 2024 | 10-Q | Quarterly Report |
| Nov 12, 2024 | 8-K | Current Report |
| Nov 07, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 07, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |